Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Long-Term Investments (2022 - 2025)

Corvus Pharmaceuticals has reported Long-Term Investments over the past 4 years, most recently at $11.5 million for Q3 2025.

  • Quarterly results put Long-Term Investments at $11.5 million for Q3 2025, down 24.08% from a year ago — trailing twelve months through Sep 2025 was $11.5 million (down 24.08% YoY), and the annual figure for FY2024 was $12.5 million, down 22.22%.
  • Long-Term Investments for Q3 2025 was $11.5 million at Corvus Pharmaceuticals, down from $11.8 million in the prior quarter.
  • Over the last five years, Long-Term Investments for CRVS hit a ceiling of $33.4 million in Q1 2022 and a floor of $11.5 million in Q3 2025.
  • Median Long-Term Investments over the past 4 years was $16.1 million (2023), compared with a mean of $18.5 million.
  • Biggest five-year swings in Long-Term Investments: tumbled 40.3% in 2023 and later fell 11.04% in 2024.
  • Corvus Pharmaceuticals' Long-Term Investments stood at $21.9 million in 2022, then fell by 26.3% to $16.1 million in 2023, then decreased by 22.22% to $12.5 million in 2024, then dropped by 8.05% to $11.5 million in 2025.
  • The last three reported values for Long-Term Investments were $11.5 million (Q3 2025), $11.8 million (Q2 2025), and $12.1 million (Q1 2025) per Business Quant data.